Article info

Original research
TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands

Authors

  1. Correspondence to Alexander Foss; alexander.foss{at}nuh.nhs.uk
View Full Text

Citation

Foss A, Haydock R, Childs M, et al
TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands

Publication history

  • Received August 6, 2020
  • Revised November 9, 2020
  • Accepted November 10, 2020
  • First published December 8, 2020.
Online issue publication 
September 09, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.